Target intelligence / Profile preview

Aspartate decarboxylase PanD (PanD)

Target
PanD
Molecular classification
Enzyme, Decarboxylase
01

Overview

Aspartate decarboxylase PanD is an essential enzyme in *Mycobacterium tuberculosis* responsible for the decarboxylation of L-aspartate to β-alanine, a critical step in the biosynthesis of coenzyme A. Pyrazinoic acid, the active metabolite of the anti-tuberculosis prodrug pyrazinamide, exerts its bactericidal effect by binding to PanD and inducing its degradation by the mycobacterial ClpC1–ClpP protease complex, leading to disruption of coenzyme A biosynthesis and subsequent bacterial death. Additionally, pyrazinoic acid acts as a protonophore, dissipating the proton motive force and disturbing cellular energetics, contributing to its killing effect. Resistance arises from mutations in panD or in the activating enzyme pyrazinamidase (pncA)[1][3][5][6][7][8][9].

Other names
PanDaspartate decarboxylase (Mycobacterium tuberculosis)MTb PanD
02

Mechanism of action

Pyrazinamide is a prodrug converted by mycobacterial pyrazinamidase to pyrazinoic acid, which binds to and disrupts PanD, leading to its degradation and inhibition of coenzyme A biosynthesis[1][3][5][9]. Pyrazinoic acid also acts as a protonophore, disrupting membrane energetics and proton motive force, which impairs cellular metabolism[6][7][8].

03

Biological functions

Coenzyme A biosynthesisCatalysis of beta-alanine formation from L-aspartate
04

Disease associations

Infection (Mycobacterium tuberculosis, Tuberculosis)
05

Safety considerations

Hepatotoxicity is a known concern for pyrazinamide but relates to drug, not target.The target itself (PanD) does not have known human homologs, making on-target toxicity less likely.Therapeutic resistance due to panD or pncA mutation is a major clinical issue[5][9].
06

Interacting drugs

Pyrazinamide (prodrug)

1 more in the full profile.

07

Biomarkers

Mutations in panD confer resistance to pyrazinamide/pyrazinoic acid in clinical isolates[3][5].Loss-of-function mutations in the pncA gene (pyrazinamidase) also indicate resistance, but this is upstream of the drug-target interaction.

Beyond the preview

Go deeper on Aspartate decarboxylase PanD (PanD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspartate decarboxylase PanD (PanD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call